The Latest Breaking News from BofA

Carlsmed Inc. (NASDAQ:CARL), an AI-powered innovator in spine surgery, is poised for significant growth following key advancements and strong analyst projections.

GoodRx stock soars after announcing GLP-1 partnership with Novo Nordisk. A Bank of America analyst recommends selling GDRX shares into the strength before they crash again.

It all comes down to the labor market, immigration, and tariffs. What is really going on in terms of how many workers are available?

Super Micro stock tanks on disappointing Q4 earnings and weaker-than-expected guidance. Here’s why SMCI shares aren’t worth buying on the post-earnings decline.

“This implies that the weak gains in payrolls in recent months might have something to do with the supply of labor.”

Ford Motor Company (NYSE:F) shares are trading higher on Thursday after the automaker posted second-quarter results that exceeded Wall Street expectations on Wednesday, driven by solid vehicle volumes and favorable pricing trends.

Pharmaceutical giants are navigating a complex landscape of fluctuating demand and regulatory hurdles, impacting their financial performance and strategic outlook. Merck Co. Inc. (NYSE:MRK) is the latest to face these challenges, as its recent earnings report reveals a mixed bag of successes and setbacks.

“Today a confluence of factors argue that the key tail risk that may not be priced in is not just a cyclical recovery, but a boom,” BofA Research analysts write.

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) announced Monday it will voluntarily and temporarily pause all U.S. shipments of Elevidys, its gene therapy for Duchenne muscular dystrophy, effective July 22.